Michael J Pencina, PhD
Adjunct Professor
Boston University School of Public Health
Dept of Biostatistics

PhD, Boston University
MA, University of Warsaw




Dr. Michael Pencina is the Duke Clinical Research Institute Director of Biostatistics. He is Professor of Biostatistics & Bioinformatics at Duke and Adjunct Professor in the Department of Biostatistics at Boston University.

As the DCRI Director of Biostatistics, Dr. Pencina serves as a key institutional leader overseeing the strategic and operational direction of our biostatistics talent and resources at the DCRI. In this role, Dr. Pencina guides a strategic vision to meet the needs of DCRI investigators by developing necessary infrastructure while also partnering with the Biostatistics & Bioinformatics Department to assure that the DCRI’s objectives and services are well understood and supported.

Prior to joining the DCRI in 2013, Dr. Pencina served as an associate professor in the Department of Biostatistics at Boston University and as Director of Statistical Consulting at the Harvard Clinical Research Institute. He brings a wealth of experience in both clinical trials and observational analyses. He has worked on a number of large clinical trials as well as Framingham Heart Study projects. Dr. Pencina is an expert in cardiovascular disease risk prediction model development and assessment of performance. The novel metrics (net reclassification improvement and integrated discrimination improvement) for the assessment of usefulness of new biomarkers and genetic factors in risk prediction proposed by Dr. Pencina have been incorporated into the reporting guidelines. For the past year, Dr. Pencina has also served as the Associate Editor for Statistics in Medicine. He has authored more than 150 manuscripts that have been published in peer-reviewed journals. Dr. Pencina earned his PhD in Mathematics and Statistics at Boston University.
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

  1. Sniderman AD, Pencina M, Thanassoulis G. ApoB. Circ Res. 2019 May 10; 124(10):1425-1427. PMID: 31070997.
     
  2. Goldstein BA, Phelan M, Pagidipati NJ, Holman RR, Pencina MJ, Stuart EA. An outcome model approach to transporting a randomized controlled trial results to a target population. J Am Med Inform Assoc. 2019 May 01; 26(5):429-437. PMID: 30869798.
     
  3. Pencina MJ, Navar AM, Wojdyla D, Sanchez RJ, Khan I, Elassal J, D'Agostino RB, Peterson ED, Sniderman AD. Quantifying Importance of Major Risk Factors for Coronary Heart Disease. Circulation. 2019 Mar 26; 139(13):1603-1611.View Related Profiles. PMID: 30586759.
     
  4. Navar AM, Peterson ED, Steen DL, Wojdyla DM, Sanchez RJ, Khan I, Song X, Gold ME, Pencina MJ. Evaluation of Mortality Data From the Social Security Administration Death Master File for Clinical Research. JAMA Cardiol. 2019 Mar 06. PMID: 30840023.
     
  5. Pencina MJ, Steyerberg EW, D'Agostino RB. Single-number summary and decision analytic measures can happily coexist. Stat Med. 2019 Feb 10; 38(3):499-500.View Related Profiles. PMID: 30609149.
     
  6. Pencina MJ, Parikh CR, Kimmel PL, Cook NR, Coresh J, Feldman HI, Foulkes A, Gimotty PA, Hsu CY, Lemley K, Song P, Wilkins K, Gossett DR, Xie Y, Star RA. Statistical methods for building better biomarkers of chronic kidney disease. Stat Med. 2019 May 20; 38(11):1903-1917. PMID: 30663113.
     
  7. Rosenstock J, Perkovic V, Johansen OE, Cooper ME, Kahn SE, Marx N, Alexander JH, Pencina M, Toto RD, Wanner C, Zinman B, Woerle HJ, Baanstra D, Pfarr E, Schnaidt S, Meinicke T, George JT, von Eynatten M, McGuire DK. Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial. JAMA. 2019 01 01; 321(1):69-79. PMID: 30418475.
     
  8. Thanassoulis G, Sniderman AD, Pencina MJ. A Long-term Benefit Approach vs Standard Risk-Based Approaches for Statin Eligibility in Primary Prevention. JAMA Cardiol. 2018 Nov 01; 3(11):1090-1095. PMID: 30422172.
     
  9. Robinson JG, Williams KJ, Gidding S, Borén J, Tabas I, Fisher EA, Packard C, Pencina M, Fayad ZA, Mani V, Rye KA, Nordestgaard BG, Tybjærg-Hansen A, Douglas PS, Nicholls SJ, Pagidipati N, Sniderman A. Eradicating the Burden of Atherosclerotic Cardiovascular Disease by Lowering Apolipoprotein B Lipoproteins Earlier in Life. J Am Heart Assoc. 2018 Oct 16; 7(20):e009778. PMID: 30371276.
     
  10. Edmonston D, Wolf M, Pencina M. Statins at Dialysis Transition-Supportive but Not Sufficient. JAMA Netw Open. 2018 Oct 05; 1(6):e182411. PMID: 30646212.
     
Showing 10 of 332 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 332 publications over 16 distinct years, with a maximum of 35 publications in 2013

YearPublications
20042
20058
20067
200713
200824
200916
201026
201132
201230
201335
201434
201531
201634
201721
201812
20197
In addition to these self-described keywords below, a list of MeSH based concepts is available here.

cardiovascular disease risk prediction model development
statistics in medicine
data science
machine learning
Contact for Mentoring:


801 Massachusetts Ave Crosstown Center
Boston MA 02118
Google Map


Pencina's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
_
Co-Authors
_
Similar People
_
Same Department